Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-25
    E.g., 2018-02-25

Articles

19185 items
12:00 AM, Apr 19, 1993  |  BioCentury | Strategy

non-cardiac surgery

Untapped market: non-cardiac surgery Dennis Mangano, a professor of anesthesiology at the University of California in San Francisco, suggests that a big growth area for cardiovascular drugs will be use in non-cardiac surgery. About 25 million...
12:00 AM, Apr 19, 1993  |  BioCentury | Strategy

Stay or go?

MicroGeneSys quandary: Stay or go? WASHINGTON - MicroGeneSys Inc., no longer the exclusive beneficiary of a $20 million appropriation to test its AIDS vaccine and unhappy with the probable conditions of an NIH-run comparison trial of...
12:00 AM, Apr 19, 1993  |  BioCentury | Strategy

TSIN

TSIN...
12:00 AM, Apr 19, 1993  |  BioCentury | Politics, Policy & Law

Genentech switches on biodiversity pact

Genentech Inc. said it has joined a business-environmental coalition that is urging the Clinton administration to sign the Convention on Biodiversity that was rejected by the Bush Administration in part on urging from biotech companies...
12:00 AM, Apr 19, 1993  |  BioCentury | Tools & Techniques

GM-CSF as immunostimulant

GM-CSF as immunostimulant Somatix Therapy Corp. said that in mouse studies GM-CSF genes inserted into inactivated melanoma cells conferred systemic immunity for at least two months in 80 percent of animals challenged with live...
12:00 AM, Apr 19, 1993  |  BioCentury | Strategy

MAbs could alter PDLI core program

Protein Design Labs Inc. acquired from Sandoz Pharma Ltd. and Sandoz Pharmaceuticals Corp. two human antiviral monoclonal antibodies that will become its lead clinical candidates, as well as the technology to produce them. That technology...
12:00 AM, Apr 19, 1993  |  BioCentury | Strategy

Glut of competition

Glut of competition Glut of competition Thrombin inhibitors or thrombin synthesis inhibitors ProductCompanyIndicationStatusHirulogBiogenUnstable anginaPhase IIIAngioplastyPhase III to startAdjunct to streptokinase in acute MI2d Phase II to startHirudinCiba-GeigyAngioplastyPhase IIIUnstable anginaPhase III to startWith tPA in MIPhase II...
12:00 AM, Apr 19, 1993  |  BioCentury | Strategy

...you say tomahto . . .

...you say tomahto . . . Judging by the debate among the principals at BioCentury, the Great Tomato Marketing Adventure of 1993 should be anticipated with enthusiasm and interest simply because it's going to be...
12:00 AM, Apr 19, 1993  |  BioCentury | Strategy

Anticoagulant crowd feels squeeze

Anticoagulant crowd feels squeeze In this era of cost-consciousness, clinical efficacy may not be enough to convince hospitals and doctors to use new products, particularly in crowded fields such as anticoagulants for acute...
12:00 AM, Apr 12, 1993  |  BioCentury | Politics, Policy & Law

Pentagon showdown for vaccine

Pentagon showdown for vaccine WASHINGTON - The controversy over the Army's plan to test MicroGeneSys Inc.'s gp160 therapeutic AIDS vaccine in an exclusive, large-scale Phase III trial may be resolved finally at a meeting to...

Pages